Largest pharmaceutical companies in the United States by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 24 pharmaceutical companies in the United States ranked by total debt, at CZK 1.5T, ahead of Pfizer (CZK 1.44T) and Merck & Co (CZK 1.1T). Figures as of 20 Nov 2026, 16:03 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AbbVieCZK 1.5T
- Median
- CZK 51B
- Combined market value
- CZK 83.89T
- Countries
- 1
- Not ranked
- 20no total debt on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | CZK 1.5T | CZK 11.35T | CZK 6,418.26 | 1.65% up | 20% up | ||
| 2 | PfizerPFE · Health Care | CZK 1.44T | CZK 3.52T | CZK 617.74 | 0.73% up | 10% up | ||
| 3 | Merck & CoMRK · Health Care | CZK 1.1T | CZK 7.44T | CZK 3,018.56 | 2.06% up | 36% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | CZK 1.07T | CZK 14.56T | CZK 6,048.82 | 1.68% up | 31% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | CZK 1T | CZK 2.69T | CZK 1,317.65 | 1.42% up | 26% up | ||
| 6 | Eli LillyLLY · Health Care | CZK 946.5B | CZK 26.9T | CZK 30,196.76 | 0.36% up | 28% up | ||
| 7 | ViatrisVTRS · Health Care | CZK 320.9B | CZK 500.1B | CZK 436.25 | 1.46% down | 90% up | ||
| 8 | Abbott LaboratoriesABT · Health Care | CZK 287.9B | CZK 4.02T | CZK 2,319.09 | 0.26% up | 19% down | ||
| 9 | ZoetisZTS · Health Care | CZK 201.4B | CZK 733.1B | CZK 1,804.23 | 0.28% up | 34% down | ||
| 10 | Royalty PharmaRPRX · Health Care | CZK 199.3B | CZK 872.4B | CZK 1,517.19 | 0.61% up | 74% up | ||
| 11 | Elanco Animal HealthELAN · Health Care | CZK 89.5B | CZK 289.4B | CZK 578.99 | 1.10% down | 18% up | ||
| 12 | Amneal PharmaceuticalsAMRX · Health Care | CZK 57.3B | CZK 165.5B | CZK 475.00 | 0.28% down | 79% up | ||
| 13 | BridgeBio PharmaBBIO · Health Care | CZK 44.7B | CZK 333.7B | CZK 1,713.15 | 1.60% down | 15% up | ||
| 14 | Regeneron PharmaceuticalsREGN · Health Care | CZK 44.2B | CZK 2.14T | CZK 20,687.68 | 0.71% up | 22% up | ||
| 15 | Ionis PharmaceuticalsIONS · Health Care | CZK 40.4B | CZK 101.3B | CZK 608.50 | 0.39% up | 64% down | ||
| 16 | InsmedINSM · Health Care | CZK 12.2B | CZK 710B | CZK 3,236.24 | 0.60% up | 27% down | ||
| 17 | Madrigal PharmaceuticalsMDGL · Health Care | CZK 7.6B | CZK 201.2B | CZK 8,659.97 | 1.98% down | 28% down | ||
| 18 | Legend BiotechLEGN · Health Care | CZK 7.1B | CZK 67.2B | CZK 346.51 | 3.35% down | 43% down | ||
| 19 | CytokineticsCYTK · Health Care | CZK 6.4B | CZK 162.7B | CZK 1,167.90 | 1.91% up | 21% down | ||
| 20 | TG TherapeuticsTGTX · Health Care | CZK 5.5B | CZK 217B | CZK 1,435.46 | 0.65% down | 103% up | ||
| 21 | Cogent BiosciencesCOGT · Health Care | CZK 5B | CZK 105.1B | CZK 604.05 | 2.22% down | 25% down | ||
| 22 | Axsome TherapeuticsAXSM · Health Care | CZK 4.2B | CZK 153.4B | CZK 2,917.02 | 3.46% down | 9% down | ||
| 23 | Rhythm PharmaceuticalsRYTM · Health Care | CZK 2.4B | CZK 174.2B | CZK 2,512.72 | 3.39% down | 15% up | ||
| 24 | Definium TherapeuticsDFTX · Health Care | CZK 903.7M | CZK 88.3B | CZK 644.69 | 1.80% down | 176% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2690 CZK). 20 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States rank first by total debt?
AbbVie (CZK 1.5T), Pfizer (CZK 1.44T) and Merck & Co (CZK 1.1T) are the top three of the 24 pharmaceutical companies in the United States ranked by total debt as of 20 Nov 2026, 16:03 UTC.
How many pharmaceutical companies in the United States are in this ranking?
24 are ranked by total debt. 20 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 24 pharmaceutical companies in the United States ranked by total debt have a combined market value of CZK 83.89T as of 20 Nov 2026, 16:03 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total debt”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.